Decoding the role of adipocyte-derived extracellular vesicle cargo in modulating distal inflammation
openNHLBI - National Heart Lung and Blood Institute
PROJECT SUMMARY/ABSTRACT
Obesity is on the rise, with over half the United States population predicted to be obese within the next
decade. Cardiovascular disease (CVD), the leading cause of death worldwide, is influenced by obesity and
is an independent risk factor for CVD. While obesity leads to metabolic complications, such as metabolic
syndrome that affects CVD, patients with obesity who are metabolically healthy are still at risk of developing
CVD. Adipose tissue (AT) inflammation occurs in obesity, with evidence suggesting its role in CVD; however,
the mechanism by which adipocytes influence vascular inflammation remains unclear. Therefore, this
multidisciplinary proposal integrates advanced mouse models, bioengineering, and artificial intelligence (AI)
to investigate how inflamed AT modulates vascular inflammation through adipocyte-derived extracellular
vesicles (AdEVs). Preliminary data demonstrate that AdEVs constitute a significant interorgan signaling
mechanism that accelerates atherosclerosis in recipient mice, particularly when harvested from obese but
not lean donors. The central hypothesis is that AT inflammation alters the bioactive cargo of AdEVs delivered
to the arterial wall, promoting vascular inflammation in tissue-resident cells while serving as a biomolecular
predictor of CVD. To address this hypothesis, the proposal is divided into three aims. Aim 1 will compare
the role of AdEVs harvested from inflamed and non-inflamed AT on inflammation and the progression of
atherosclerosis. Aim 2 will utilize an integrated AI model to identify bioactive cargo in AdEVs from inflamed
AT, engineer AdEVs to overexpress candidate cargo, and evaluate their effects on inflammation and
atherosclerosis. Lastly, in Aim 3, disease-inducing cargo in AdEVs, in conjunction with machine learning
(ML), will be utilized as a prognostic assay for CVD. The proposal will be conducted under the primary
mentorship of Dr. Willa A. Hsueh, a leading physician-scientist in the field of immunometabolism. During the
K99 mentored phase, the candidate will receive formal training in metabolic phenotyping, flow cytometry,
vascular biology, immunology, AdEV bioengineering, AI/ML, and clinical translation for obesity and CVD. To
achieve these goals, the candidate assembled a multidisciplinary mentorship team comprising experts in
extracellular vesicle (EV) cargo loading, AI/ML, CVD clinical translation, and EV characterization. The
multidisciplinary mentorship team and comprehensive training plan, along with the collaborative research
environment and cutting-edge resources provided by The Ohio State University, position the candidate for
a successful transition to an independent career during the R00 phase, with the long-term goal of
establishing a research program on adipocyte interorgan signaling at the interface of bioengineering and
medicine. This proposal has the potential to advance mechanistic understanding of CVD, enabling AdEV-
based early-detection prognostic assays in the short term and informing novel therapeutics in the long term.
Up to $122K
health research